Group Iii, Lp Svennilson Pe... Net Worth

Insiders trading at Revolution Medicines Inc

Over the last 5 years, insiders at Revolution Medicines Inc have traded over 249,645,422$ worth of Revolution Medicines Inc stock and bought 3,371,315 units worth 74,500,278$ . The most active insiders traders include Peter Svennilson、Thilo Schroeder、Rock Ventures Ii, L.P.Third.... On average, Revolution Medicines Inc executives and independent directors trade stock every 11 days with the average trade being worth of 3,075,216$. The most recent stock trade was executed by Stephen Michael Kelsey on 13 August 2024, trading 16,667 units of RVMD stock currently worth 68,168$.

What does Revolution Medicines Inc do?

revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.

Revolution Medicines Inc executives and stock owners

Revolution Medicines Inc executives and other stock owners filed with the SEC include:

• Mark Goldsmith,
  Chairman of the Board, President, Chief Executive Officer
• Margaret Horn,
  Chief Operating Officer, General Counsel
• Steve Kelsey,
  President of Research and Development
• Dr. Mark A. Goldsmith Ph.D.,
  CEO, Pres & Chairman
• Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.,
  Pres of R&D
• Margaret A. Horn J.D.,
  COO, Gen. Counsel & Sec.
• Dr. Stephen M. Kelsey M.D., FRCP, FRC Path.,
  Pres of R&D
• Margaret A. Horn,
  COO, Gen. Counsel & Sec.
• Xiaolin Wang,
  Exec. VP of Clinical Devel.
• Dr. Mark A. Goldsmith M.D., Ph.D.,
  CEO, Pres & Chairman
• Alexis Borisy,
  Lead Independent Director
• Barbara Weber,
  Independent Director
• Vincent Miller,
  Independent Director
• Elizabeth Anderson,
  Independent Director
• Peter Svennilson,
  Independent Director
• Thilo Schroeder,
  Independent Director
• Eric Schmidt,
  Independent Director
• Neil Exter,
  Independent Director
• Jack Anders,
  Vice President - Finance and Principal Accounting Officer
• Dr. Martin D. Burke M.D., Ph.D.,
  Co-Founder & Chairman of Scientific Advisory Board
• Jack Anders,
  Sr. VP of Fin. & Principal Accounting Officer
• Luan M. Wilfong,
  Sr. VP of HR
• Walter Reiher Ph.D.,
  Chief Information Officer
• David L. Pompliano,
  Founding Chief Scientific Officer
• Dr. Kevan M. Shokat,
  Academic Co-Founder & Member of Scientific Advisory Board
• Dr. Michael A. Fischbach,
  Academic Co-Founder & Member of Scientific Advisory Board
• Dr. Martin D. Burke,
  Co-Founder & Chairman of Scientific Advisory Board
• Frank Clyburn,
  
• Group Iii, Lpcolumn Group I...,
  
• Laurence Lasky,
  Director
• Group Iii, Lp Svennilson Pe...,
  
• Rock Ventures Iii, L.P.Thir...,
  
• Rock Ventures Iv, L.P.Third...,
  
• James E Deerfield Mgmt Iv, ...,
  
• Lin Wei,
  Chief Medical Officer
• Jeff Cislini,
  General Counsel
• Stephen Michael Kelsey,
  See Remarks
• Rock Ventures Iii, L.P.Thir...,
  
• Rock Ventures Iii, L.P.Thir...,
  
• Xiaolin Wang,
  See Remarks
• Rock Ventures Ii, L.P.Third...,
  
• Rock Ventures Iii, L.P.Thir...,
  
• Sushil Patel,
  
• Flavia Borellini,
  
• Lorence H. Kim,